# COVID supplement: Tetramer Research & Development

> **NIH NIH N01** · EMORY UNIVERSITY · 2022 · $200,000

## Abstract

The NIH Tetramer Core Facility provides valuable resources to the research community that enable cutting edge research in basic immunology (such as SARS-CoV-2) and a wide variety of infectious disease areas via production and distribution of class I, class II and CD1 reagents. The reagents are being applied to studies of antigen processing and presentation, T cell activation, T cell responses against microbial pathogens or tumors, and T cell-mediated exacerbation or amelioration of immune-mediated diseases. This contract conducts research and development that would enhance the quality, functionality (e.g., sensitivity), and breadth of available tetramer reagents and decrease production time.

## Key facts

- **NIH application ID:** 10678174
- **Project number:** 75N93020D00005-0-759302200001-2
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** JOHN ALTMAN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $200,000
- **Award type:** —
- **Project period:** 2020-03-21 → 2027-03-20

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10678174

## Citation

> US National Institutes of Health, RePORTER application 10678174, COVID supplement: Tetramer Research & Development (75N93020D00005-0-759302200001-2). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/10678174. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*